Kamlesh Khunti to Cardiovascular Diseases
This is a "connection" page, showing publications Kamlesh Khunti has written about Cardiovascular Diseases.
Connection Strength
2.191
-
Long COVID - metabolic risk factors and novel therapeutic management. Nat Rev Endocrinol. 2021 07; 17(7):379-380.
Score: 0.153
-
Indirect impact of the COVID-19 pandemic on hospitalisations for cardiometabolic conditions and their management: A systematic review. Prim Care Diabetes. 2021 08; 15(4):653-681.
Score: 0.152
-
COVID-19, ethnicity and cardiometabolic disease self-management in UK primary care. Diabetes Metab Syndr. 2020 Nov-Dec; 14(6):2241-2243.
Score: 0.147
-
COVID-19 and ethnicity: A novel pathophysiological role for inflammation. Diabetes Metab Syndr. 2020 Sep - Oct; 14(5):1043-1051.
Score: 0.143
-
Therapeutic uncertainties in people with cardiometabolic diseases and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2 or COVID-19). Diabetes Obes Metab. 2020 10; 22(10):1942-1945.
Score: 0.142
-
Cardiovascular and mortality events in type 2 diabetes cardiovascular outcomes trials: a systematic review with trend analysis. Acta Diabetol. 2019 Mar; 56(3):331-339.
Score: 0.128
-
Improving quality in cardiometabolic medicine real-world evidence. Prim Care Diabetes. 2019 04; 13(2):188.
Score: 0.128
-
Cardiovascular, cancer and mortality events after bariatric surgery in people with and without pre-existing diabetes: A nationwide study. J Diabetes. 2019 Apr; 11(4):265-272.
Score: 0.127
-
Legacy benefits of blood glucose, blood pressure and lipid control in individuals with diabetes and cardiovascular disease: Time to overcome multifactorial therapeutic inertia? Diabetes Obes Metab. 2018 06; 20(6):1337-1341.
Score: 0.122
-
Do sulphonylureas still have a place in clinical practice? Lancet Diabetes Endocrinol. 2018 10; 6(10):821-832.
Score: 0.122
-
Association of walking pace and handgrip strength with all-cause, cardiovascular, and cancer mortality: a UK Biobank observational study. Eur Heart J. 2017 Nov 14; 38(43):3232-3240.
Score: 0.119
-
Association Between Adherence to Pharmacotherapy and Outcomes in Type 2 Diabetes: A Meta-analysis. Diabetes Care. 2017 11; 40(11):1588-1596.
Score: 0.117
-
Associations Between Anthropometric Measurements and Cardiometabolic Risk Factors in White European and South Asian Adults in the United Kingdom. Mayo Clin Proc. 2017 06; 92(6):925-933.
Score: 0.116
-
Excess deaths in people with cardiovascular diseases during the COVID-19 pandemic. Eur J Prev Cardiol. 2021 12 20; 28(14):1599-1609.
Score: 0.040
-
Prevalence of co-morbidities and their association with mortality in patients with COVID-19: A systematic review and meta-analysis. Diabetes Obes Metab. 2020 10; 22(10):1915-1924.
Score: 0.036
-
Addressing cardiovascular risk in type 2 diabetes mellitus: a report from the European Society of Cardiology Cardiovascular Roundtable. Eur Heart J. 2019 09 07; 40(34):2907-2919.
Score: 0.034
-
Association of smoking and cardiometabolic parameters with albuminuria in people with type 2 diabetes mellitus: a systematic review and meta-analysis. Acta Diabetol. 2019 Aug; 56(8):839-850.
Score: 0.033
-
Causality between non-alcoholic fatty liver disease and risk of cardiovascular disease and type 2 diabetes: A meta-analysis with bias analysis. Liver Int. 2019 03; 39(3):557-567.
Score: 0.032
-
Effects of intensive interventions compared to standard care in people with type 2 diabetes and microalbuminuria on risk factors control and cardiovascular outcomes: A systematic review and meta-analysis of randomised controlled trials. Diabetes Res Clin Pract. 2018 Dec; 146:76-84.
Score: 0.032
-
Online patient education interventions in type 2 diabetes or cardiovascular disease: A systematic review of systematic reviews. Prim Care Diabetes. 2019 02; 13(1):16-27.
Score: 0.031
-
SGLT-2 Inhibitors and Cardiovascular Risk: An Analysis of CVD-REAL. J Am Coll Cardiol. 2018 06 05; 71(22):2497-2506.
Score: 0.031
-
What have we learnt from "real world" data, observational studies and meta-analyses. Diabetes Obes Metab. 2018 02; 20 Suppl 1:47-58.
Score: 0.030
-
Long-term Effects of Statins, Blood Pressure-Lowering, and Both on Erectile Function in Persons at Intermediate Risk for Cardiovascular Disease: A Substudy of the Heart Outcomes Prevention Evaluation-3 (HOPE-3) Randomized Controlled Trial. Can J Cardiol. 2018 01; 34(1):38-44.
Score: 0.030
-
Real-world use and modeled impact of glucose-lowering therapies evaluated in recent cardiovascular outcomes trials: An NCDR® Research to Practice project. Eur J Prev Cardiol. 2017 10; 24(15):1637-1645.
Score: 0.029
-
Comorbidities, complications and mortality in people of South Asian ethnicity with type 1 diabetes compared with other ethnic groups: a systematic review. BMJ Open. 2017 Jul 13; 7(7):e015005.
Score: 0.029
-
Evaluation of community provision of a preventive cardiovascular programme - the National Health Service Health Check in reaching the under-served groups by primary care in England: cross sectional observational study. BMC Health Serv Res. 2017 06 14; 17(1):405.
Score: 0.029
-
Management of lipid-lowering therapy in patients with cardiovascular events in the UK: a retrospective cohort study. BMJ Open. 2017 05 10; 7(5):e013851.
Score: 0.029
-
Vascular risk checks in the UK: strategic challenges for implementation. Heart. 2009 Jun; 95(11):866-7.
Score: 0.016
-
Post-covid syndrome in individuals admitted to hospital with covid-19: retrospective cohort study. BMJ. 2021 03 31; 372:n693.
Score: 0.009
-
A cluster randomized controlled trial of the effectiveness and cost-effectiveness of intermediate care clinics for diabetes (ICCD): study protocol for a randomized controlled trial. Trials. 2012 Sep 12; 13:164.
Score: 0.005